Liquid biopsy in Ewing sarcoma and osteosarcoma as a prognostic and response diagnostic: The LEOPARD Study

Dr. David Shulman is a pediatric oncologist at Dana-Farber Cancer Institute. He studies novel therapies and biomarkers for patients with advanced sarcomas. In addition to early phase clinical trials, Dr. Shulman co-leads an effort to evaluate circulating tumor DNA, a type of "liquid biopsy," as a potential tool to improve the ways in which we treat patients with bone and soft tissue sarcomas. He joins us on OsteoBites to discuss the LEOPARD Study: Liquid Biopsy in Ewing sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic